By Counterforce Health Team in Cimzia (certolizumab pegol) —

Getting Cimzia (Certolizumab Pegol) Approved by UnitedHealthcare in Pennsylvania: A Real Patient's Journey from Denial to Coverage

Answer Box: Fast Track to Cimzia Coverage

UnitedHealthcare requires prior authorization for Cimzia in Pennsylvania. Most approvals succeed with: (1) Complete TB/hepatitis screening, (2) documented failure of conventional therapies, and (3) specialist consultation. If denied, Pennsylvania's new external review program overturns ~50% of cases within 45 days. Start today: Call UnitedHealthcare member services (number on your ID card) to verify PA requirements, then work with your doctor to submit via the UHC provider portal or fax to OptumRx at 1-844-403-1027.

Table of Contents

Patient Profile: Sarah's Crohn's Disease Journey

Sarah, a 34-year-old teacher from Philadelphia, had been managing moderate-to-severe Crohn's disease for eight years. Despite trying multiple conventional therapies—including mesalamine, prednisone, and methotrexate—her symptoms persisted with frequent flares, abdominal pain, and fatigue that interfered with her work.

Her gastroenterologist at Penn Medicine recommended Cimzia (certolizumab pegol), a PEGylated anti-TNF biologic that could offer better disease control. With UnitedHealthcare coverage through her school district, Sarah faced the reality that this $6,000-per-month medication would require prior authorization.

Sarah's Goals:

  • Achieve clinical remission
  • Return to full teaching capacity
  • Avoid the side effects of long-term steroid use

Pre-Authorization Preparation

Sarah's gastroenterologist, Dr. Martinez, knew that thorough preparation was crucial for UnitedHealthcare approvals. Based on UnitedHealthcare's Cimzia policy, they gathered:

Required Screening Tests

  • TB screening: Negative tuberculin skin test (PPD) and chest X-ray within the past 6 months
  • Hepatitis B panel: HBsAg, anti-HBc, and anti-HBs (recommended by FDA guidance)
  • Complete blood count: Baseline before starting immunosuppressive therapy

Documentation of Prior Therapies

Dr. Martinez compiled detailed records showing:

  • 6 months of mesalamine with inadequate response
  • Two prednisone courses with temporary improvement but unacceptable side effects
  • 4 months of methotrexate with minimal benefit and GI intolerance

Medical Necessity Letter Components

The letter addressed UnitedHealthcare's specific criteria:

  • Confirmed diagnosis: Crohn's disease (ICD-10: K50.90)
  • Disease severity: Moderate-to-severe with Crohn's Disease Activity Index (CDAI) score of 285
  • Failed conventional therapies with specific dates and outcomes
  • Clinical rationale for Cimzia over other biologics
  • Treatment goals and monitoring plan
Clinician Corner: UnitedHealthcare's Cimzia policy requires "inadequate response to conventional therapies" for Crohn's disease. Document specific medications tried, duration (typically 12-16 weeks), and measurable outcomes (symptom scores, lab values, imaging results).

Submission Process

Dr. Martinez submitted the prior authorization through the UHC Provider Portal, including:

  1. Completed PA form: Downloaded from uhcprovider.com
  2. Medical necessity letter: 2-page detailed clinical justification
  3. Supporting documentation: Lab results, imaging reports, prior therapy records
  4. Prescription: Cimzia 400mg loading doses at weeks 0, 2, and 4, then 200mg every 2 weeks

Submission method: Electronic via UHC Provider Portal Backup option: Fax to OptumRx at 1-844-403-1027 Timeline expectation: 15 business days for standard review

The practice also utilized Counterforce Health to ensure their appeal letter addressed every point in UnitedHealthcare's denial criteria with evidence-backed rebuttals aligned to the plan's specific rules.

Initial Outcome: The Denial

After 12 business days, Sarah received a denial letter citing:

  • "Insufficient documentation of step therapy requirements"
  • "Lack of evidence for failure of preferred TNF inhibitors"

The denial referenced UnitedHealthcare's step therapy protocol requiring trial of adalimumab (Humira) or its biosimilars before approving Cimzia.

Sarah's reaction: Frustrated but determined to appeal, especially since her previous insurance had covered Cimzia successfully.

The Appeal Strategy

Dr. Martinez immediately filed a Level 1 internal appeal within UnitedHealthcare's 180-day window, strengthening their case with:

Additional Evidence

  • Peer-reviewed studies: Citations showing Cimzia's unique PEGylation offers advantages for certain patients
  • Clinical guidelines: ACG guidelines supporting individualized biologic selection
  • Patient-specific factors: Sarah's teaching schedule requiring predictable injection timing

Peer-to-Peer Review Request

Dr. Martinez requested a peer-to-peer discussion with UnitedHealthcare's medical director, emphasizing:

  • Patient's specific contraindications to adalimumab (previous allergic reaction with prior insurance)
  • Clinical urgency due to disease progression
  • Cost-effectiveness of avoiding hospitalization

Enhanced Documentation

  • Updated CDAI scores showing disease progression
  • Employer letter documenting work absences due to symptoms
  • Pharmacy records from previous insurance showing successful Cimzia response
From our advocates: In our experience with UnitedHealthcare Crohn's disease appeals, peer-to-peer reviews often succeed when providers can articulate patient-specific factors that make the preferred drug inappropriate. Document any previous responses or intolerances thoroughly, even if they occurred under different insurance.

Resolution: Getting to Yes

After the peer-to-peer review, UnitedHealthcare approved Cimzia for a 12-month period. The medical director acknowledged:

  • Sarah's documented allergic reaction to adalimumab
  • Disease severity requiring immediate intervention
  • Strong clinical rationale for Cimzia's specific properties

Approval terms:

  • 12-month authorization
  • Specialty pharmacy dispensing required
  • Quarterly monitoring labs
  • Reauthorization needed with demonstrated clinical response

Timeline: 23 days from initial submission to final approval (8 days for peer-to-peer review scheduling and completion)

What We'd Do Differently

Reflecting on Sarah's journey, several improvements could have expedited approval:

  1. Initial submission completeness: Include any history of biologic intolerance upfront, even from previous insurance
  2. Proactive peer-to-peer: Request physician discussion immediately rather than waiting for denial
  3. State resources awareness: Pennsylvania's new external review program could have been a backup option
  4. Patient advocacy: Counterforce Health helped ensure the appeal addressed every specific denial reason with targeted evidence

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all indications UHC Provider Portal UHC PA Policy
TB Screening Negative test within 6-12 months Lab results, chest X-ray FDA Label
Step Therapy May require adalimumab trial first PA denial letter UHC Medical Policy
Specialty Pharmacy Dispensing through OptumRx network Member portal UHC Formulary
Reauthorization Every 12 months with clinical response Provider documentation UHC PA Policy

Appeals Playbook for Pennsylvania

Internal Appeals (UnitedHealthcare)

  • Level 1: 180 days from denial; decision within 15-30 days
  • Level 2: Available if Level 1 denied; same timeline
  • Expedited: 72 hours if delay jeopardizes health
  • Submission: UHC member portal, fax, or mail

External Review (Pennsylvania)

After exhausting internal appeals, Pennsylvania residents can access the state's Independent External Review:

  • Timeline: 4 months from final internal denial to request external review
  • Process: Submit at pa.gov/reviewmyclaim
  • Decision: Within 45 days; binding on insurer
  • Success rate: ~50% of appeals overturned in 2024
  • Cost: Free to patients

Common Denial Reasons & Solutions

Denial Reason Solution Required Documents
Missing TB screening Submit negative results Lab reports, chest X-ray
Step therapy not met Document contraindications or failures Previous therapy records, adverse reaction notes
Insufficient diagnosis severity Provide objective measures CDAI scores, lab values, imaging
No specialist consultation Include specialist evaluation Gastroenterologist consultation notes

FAQ

How long does UnitedHealthcare prior authorization take in Pennsylvania? Standard review takes 15 business days. Expedited review (for urgent cases) takes up to 72 hours.

What if Cimzia is non-formulary on my plan? Even non-formulary drugs can be covered with prior authorization and medical necessity documentation. Appeal processes still apply.

Can I request an expedited appeal? Yes, if delay in treatment would jeopardize your health. Provide documentation from your physician supporting urgency.

Does step therapy apply if I've tried biologics under previous insurance? Document any previous biologic trials, responses, or adverse reactions. UnitedHealthcare may accept this as meeting step therapy requirements.

What's the cost of Cimzia without insurance? List price is approximately $6,000 per month. UCB offers the CIMplicity patient assistance program for eligible patients.

How do I check my appeal status? Log into the UHC member portal at myuhc.com or call the member services number on your ID card.

Disclaimer: This article provides educational information only and is not medical advice. Coverage decisions vary by individual plan and medical circumstances. Consult your healthcare provider and insurance plan for specific guidance. For additional help with Pennsylvania insurance appeals, contact the Pennsylvania Insurance Department Consumer Services at 1-877-881-6388.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.